Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
about
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeA critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorderCurrent and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyA Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar DisorderRecommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychoticsEffectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoateCost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.The treatment of schizophrenia: Can we raise the standard of care?Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review.Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia.Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophrenia.Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results.Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France.Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists.Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1.Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2.Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
P2860
Q26752965-E84CEB83-81C5-4DE2-8E76-A99085E3E159Q26766541-6CBC7689-272B-44A2-BDC8-7407793929F9Q30382281-48F67F28-DBCB-4389-89E6-24BB1B98B5DAQ33650097-8C066743-DD53-46E0-992B-20C2FFAB3BE1Q33759300-181EAAE1-E38A-4B5B-9ED5-AD9B5B672F01Q34418847-D9F69B0F-EC6D-4C8B-AD6A-720303B73D0EQ34676317-A1C589B3-B120-411D-BD33-8FF28BF7F719Q35965634-FAADB02A-40C1-4FFB-8EF5-00411B74D43BQ35984960-B75B9610-93C9-4A8A-AE5A-13E5DCF53D76Q36467615-F08F3781-DC36-41A5-9FBD-467772A6B3B1Q36568895-E8730C5D-3826-490D-9D1D-2A1210198113Q36698856-3D2C2D40-927B-4E2B-BE65-31E4427FDFFCQ36981526-AE0B2F94-1D71-4F99-9F19-B7E6347185E2Q37465729-2E7CD6A0-23B9-424A-844F-5CDF365815F6Q38233228-92A0B8B6-7903-4A19-844B-BA608F56A58FQ38570636-6B66C91B-CFD5-4DD1-AE77-673EAA72024DQ38659006-AF1AC0A8-370E-44C3-8416-BC26DA36E88FQ38694855-0222B701-4A23-4BDB-BD04-1F8509EF1967Q38851123-0DE33FBC-E725-4B82-B304-C5C8FF4E79F8Q39002140-80B9F203-1311-4AB4-BF3E-3CB14CEE9DF8Q39038512-94F42425-9851-466A-8352-88C00DD0BECBQ39073819-9C5FCC2C-632E-4C7C-9C72-1B7E56F5FE6EQ40512185-C3C41CCD-F031-4A0D-9380-608B740DB99BQ41633896-661D375B-B758-47C1-9460-03CE55120E2EQ47154075-59FB7CB9-31B5-460C-996E-3C9DA3ED651FQ47551032-656856E9-1B7F-49E7-BF4E-C5AADE434B6BQ47574118-A20B42CD-08DD-4050-9F4B-B557CDC02AFEQ47927730-3DFFEAAD-B631-44D5-82F7-7206AC543D82Q47998008-DD27032C-4617-49DA-9403-DC792C7931FDQ48059462-3E7E5647-3004-4D26-B677-665D84727294Q49222117-591AD127-B5AB-400B-9010-995B9C78CF8BQ50140700-06F0CEC8-064C-4A1C-85E2-630C80BCB307Q50541514-B4EC27B7-55DC-4ED5-9ECE-80867EF3DA3DQ51731261-A518D8F8-CE7A-4851-A30D-27C60AF70E33Q55364906-2D59203D-D09A-45F0-AC22-A1B6CA34770DQ55438360-A21F4015-1374-496E-A266-09C69F0BFB8CQ58749200-313A138A-304C-43FC-8397-31A9FFAA8C32
P2860
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Guidelines for the use and man ...... ics in serious mental illness.
@ast
Guidelines for the use and man ...... ics in serious mental illness.
@en
type
label
Guidelines for the use and man ...... ics in serious mental illness.
@ast
Guidelines for the use and man ...... ics in serious mental illness.
@en
prefLabel
Guidelines for the use and man ...... ics in serious mental illness.
@ast
Guidelines for the use and man ...... ics in serious mental illness.
@en
P2093
P2860
P50
P356
P1433
P1476
Guidelines for the use and man ...... ics in serious mental illness.
@en
P2093
Mocrane Abbar
Philippe Courtet
Sylvie Lancrenon
P2860
P2888
P356
10.1186/1471-244X-13-340
P577
2013-12-20T00:00:00Z
P5875
P6179
1026074048